|
21 Companies |
|
27 Products |
|
27 Products |
|
9 Mechanisms of Action |
|
1 Trial |
|
379 News |
|
| 12345678» |
- || Kisunla (donanemab-azbt) / Eli Lilly
Enrollment change: A Study of LY3002813 in Participants With Alzheimer's Disease (clinicaltrials.gov) - Oct 4, 2024
P1, N=63, Completed, Sponsor: Eli Lilly and Company
N=100 --> 63
- | NN1213 / Novo Nordisk
Trial completion: PET Imaging in MCI Following ADT for PCa (clinicaltrials.gov) - Dec 7, 2023
P=N/A, N=11, Completed, Sponsor: Imperial College London
N=100 --> 63 Suspended --> Completed
- | NN1213 / Novo Nordisk
Phase classification: Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia (Allena-Mente). (clinicaltrials.gov) - Sep 13, 2023
P=N/A, N=121, Completed, Sponsor: Fondazione Golgi Cenci
Suspended --> Completed Phase classification: P2 --> P=N/A
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, HEOR: Behavioral Interventions to Prevent or Delay Dementia (clinicaltrials.gov) - Feb 22, 2019
P=N/A, N=272, Completed, Sponsor: Mayo Clinic
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed | N=600 --> 272 | Trial completion date: Dec 2018 --> Mar 2018 | Trial primary completion date: Dec 2018 --> Mar 2018
- | Phase classification, Enrollment change: Mild Cognitive Impairment and Obstructive Sleep Apnea (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=54, Completed, Sponsor: George Mason University
Active, not recruiting --> Completed | N=600 --> 272 | Trial completion date: Dec 2018 --> Mar 2018 | Trial primary completion date: Dec 2018 --> Mar 2018 Phase classification: P3 --> P=N/A | N=86 --> 54
- | NN1213 / Novo Nordisk
Enrollment change, Trial withdrawal: Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel (clinicaltrials.gov) - Jan 18, 2019
P=N/A, N=0, Withdrawn, Sponsor: Uniformed Services University of the Health Sciences
Phase classification: P3 --> P=N/A | N=86 --> 54 N=150 --> 0 | Recruiting --> Withdrawn
- | donepezil / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Donepezil and the Risk of Falls in Seniors With Cognitive Impairment (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=60, Completed, Sponsor: Lawson Health Research Institute
N=150 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jan 2019 | Trial primary completion date: Jun 2017 --> Jan 2019
- | Enrollment change: Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV (clinicaltrials.gov) - Oct 23, 2018
P=N/A, N=146, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jan 2019 | Trial primary completion date: Jun 2017 --> Jan 2019 N=360 --> 146
- | NN1213 / Novo Nordisk
Enrollment change, Trial withdrawal, HEOR: Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II (clinicaltrials.gov) - Oct 15, 2018
P3, N=0, Withdrawn, Sponsor: University of California, Los Angeles
N=360 --> 146 N=1500 --> 0 | Not yet recruiting --> Withdrawn
- | NN1213 / Novo Nordisk
Trial completion, Phase classification, Trial completion date: Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation (clinicaltrials.gov) - Aug 31, 2018
P=N/A, N=44, Completed, Sponsor: VA Office of Research and Development
N=1500 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Dec 2018 --> Mar 2017
- | Trial completion, Trial completion date, Trial primary completion date: IU-CHOICE: Indiana University Dementia Screening Trial (clinicaltrials.gov) - Aug 27, 2018
P=N/A, N=4000, Completed, Sponsor: Indiana University
Active, not recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Dec 2018 --> Mar 2017 Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Nov 2017 | Trial primary completion date: Feb 2017 --> Nov 2017
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Study of tDCS for Mild Cognitive Impairment (clinicaltrials.gov) - Aug 8, 2018
P=N/A, N=16, Completed, Sponsor: Incheon St.Mary's Hospital
Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Nov 2017 | Trial primary completion date: Feb 2017 --> Nov 2017 Recruiting --> Completed | N=24 --> 16 | Trial completion date: Apr 2015 --> Oct 2015 | Trial primary completion date: Mar 2015 --> Oct 2015
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: ACES: The Aerobic & Cognitive Exercise Study (clinicaltrials.gov) - May 3, 2018
P=N/A, N=111, Completed, Sponsor: Union College, New York
Recruiting --> Completed | N=24 --> 16 | Trial completion date: Apr 2015 --> Oct 2015 | Trial primary completion date: Mar 2015 --> Oct 2015 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Jul 2017 | Trial primary completion date: Jun 2016 --> Jul 2017
- | Trial completion: UCLA Fitness and Memory Study of Activity In Mild Cognitive Impairment (AIM) (clinicaltrials.gov) - May 2, 2018
P=N/A, N=35, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Jul 2017 | Trial primary completion date: Jun 2016 --> Jul 2017 Terminated --> Completed
- | Trial completion: Shanghai Mild Cognitive Impairment Cohort Study (clinicaltrials.gov) - Apr 25, 2018
P=N/A, N=400, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Terminated --> Completed Active, not recruiting --> Completed
- | verubecestat (MK-8931) / Merck (MSD)
Trial termination: APECS: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (clinicaltrials.gov) - Apr 24, 2018
P3, N=1454, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- | Trial completion, Trial completion date, Trial primary completion date: UEE-SAS: Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=30, Completed, Sponsor: Slovak Academy of Sciences
Active, not recruiting --> Terminated Recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2018 | Trial primary completion date: Dec 2015 --> Sep 2017
- | Trial completion: A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Apr 5, 2018
P=N/A, N=72, Completed, Sponsor: Palo Alto Veterans Institute for Research
Recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2018 | Trial primary completion date: Dec 2015 --> Sep 2017 Active, not recruiting --> Completed
- |||| verubecestat (MK-8931) / Merck (MSD)
Trial completion date, Trial primary completion date: APECS: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (clinicaltrials.gov) - Mar 30, 2018
P3, N=1350, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial completion date: Mar 2021 --> Apr 2018 | Trial primary completion date: Feb 2019 --> Apr 2018
- | Trial completion date, Trial primary completion date, HEOR: Behavioral Interventions to Prevent or Delay Dementia (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=600, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Mar 2021 --> Apr 2018 | Trial primary completion date: Feb 2019 --> Apr 2018 Trial primary completion date: Mar 2018 --> Dec 2018 | Trial completion date: Mar 2018 --> Dec 2018
- Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=97, Terminated, Sponsor: Enzymotec
Trial primary completion date: Mar 2018 --> Dec 2018 | Trial completion date: Mar 2018 --> Dec 2018 N=360 --> 97 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Dec 2017 | Trial completion date: Sep 2019 --> Dec 2017; Due to difficulties in patient recruitment
- | Trial completion, Enrollment change: NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment (clinicaltrials.gov) - Jan 24, 2018
P2, N=24, Completed, Sponsor: Chang Gung Memorial Hospital
N=360 --> 97 | Recruiting --> Terminated | Trial primary completion date: Sep 2017 --> Dec 2017 | Trial completion date: Sep 2019 --> Dec 2017; Due to difficulties in patient recruitment Recruiting --> Completed | N=50 --> 24
- | Trial completion, Trial initiation date, Trial primary completion date: Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment (clinicaltrials.gov) - Jan 18, 2018
P3, N=200, Completed, Sponsor: Thomas Jefferson University
Recruiting --> Completed | N=50 --> 24 Active, not recruiting --> Completed | Initiation date: Sep 2010 --> Jun 2011 | Trial primary completion date: Dec 2017 --> Dec 2016
- ||| Kisunla (donanemab-azbt) / Eli Lilly
Trial completion, Trial primary completion date: A Study of LY3002813 in Participants With Alzheimer's Disease (clinicaltrials.gov) - Dec 26, 2017
P1, N=100, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | Initiation date: Sep 2010 --> Jun 2011 | Trial primary completion date: Dec 2017 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2016
- | Biomarker, New trial: Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=60, Completed, Sponsor: Duke University
- | Biomarker, Trial completion: Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease (clinicaltrials.gov) - Dec 18, 2017
P=N/A, N=60, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2016 Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Retaining Cognition While Avoiding Late-Life Depression (clinicaltrials.gov) - Nov 14, 2017
P=N/A, N=94, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=136 --> 94
- | Phase classification, HEOR: Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II (clinicaltrials.gov) - Oct 31, 2017
P3, N=1500, Not yet recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | N=136 --> 94 Phase classification: P=N/A --> P3
- || Kisunla (donanemab-azbt) / Eli Lilly
Trial primary completion date: A Study of LY3002813 in Participants With Alzheimer's Disease (clinicaltrials.gov) - Sep 25, 2017
P1, N=100, Active, not recruiting, Sponsor: Eli Lilly and Company
Phase classification: P=N/A --> P3 Trial primary completion date: Aug 2017 --> Nov 2017
- | Trial completion: Brain-Computer Interface System for Training Memory and Attention in Elderly (clinicaltrials.gov) - Aug 2, 2017
P2, N=240, Completed, Sponsor: Duke-NUS Graduate Medical School
Trial primary completion date: Aug 2017 --> Nov 2017 Recruiting --> Completed
- | Phase classification, Combination therapy: Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI) (clinicaltrials.gov) - Jul 28, 2017
P2/3, N=330, Completed, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed Phase classification: P4 --> P2/3
- | Trial completion, Trial primary completion date: Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=108, Completed, Sponsor: Chang Gung Memorial Hospital
Phase classification: P4 --> P2/3 Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2016
- || ladostigil hemitartrate (TV-3326) / Avraham
Trial primary completion date: A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (clinicaltrials.gov) - Jun 15, 2017
P2, N=210, Completed, Sponsor: Avraham Pharmaceuticals Ltd
Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- |||| Trial completion, Trial primary completion date: Clinical Evaluation of Florbetapir F 18 (18F-AV-45) (clinicaltrials.gov) - Jun 12, 2017
P2, N=1772, Completed, Sponsor: Avid Radiopharmaceuticals
Trial primary completion date: Dec 2015 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2017
- | Enrollment closed: Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation (clinicaltrials.gov) - May 31, 2017
P1, N=40, Active, not recruiting, Sponsor: VA Office of Research and Development
Recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2017 Recruiting --> Active, not recruiting
- | Enrollment closed, Trial primary completion date, HEOR: Behavioral Interventions to Prevent or Delay Dementia (clinicaltrials.gov) - May 19, 2017
P=N/A, N=600, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2018
- | Trial completion, Trial primary completion date: ProsKuopio: Computational Tools for Early Diagnosis of Memory Disorders (clinicaltrials.gov) - May 3, 2017
P=N/A, N=126, Completed, Sponsor: University of Eastern Finland
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2018 Enrolling by invitation --> Completed | Trial primary completion date: Jun 2016 --> Apr 2017
- | Trial completion: Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) (clinicaltrials.gov) - May 2, 2017
P=N/A, N=710, Completed, Sponsor: University of California, Los Angeles
Enrolling by invitation --> Completed | Trial primary completion date: Jun 2016 --> Apr 2017 Recruiting --> Completed
- | Phase classification, Trial primary completion date: The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly (clinicaltrials.gov) - Apr 26, 2017
P, N=44, Completed, Sponsor: Tufts University
Recruiting --> Completed Phase classification: P=N/A --> P | Trial primary completion date: Jul 2014 --> Aug 2015
- | Trial primary completion date: Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment (clinicaltrials.gov) - Apr 25, 2017
P3, N=200, Active, not recruiting, Sponsor: Thomas Jefferson University
Phase classification: P=N/A --> P | Trial primary completion date: Jul 2014 --> Aug 2015 Trial primary completion date: Dec 2016 --> Dec 2017
- | Biomarker, Trial completion, Trial primary completion date: PACE-2: Piedmont Aging, Cognition & Exercise Study-2 (clinicaltrials.gov) - Apr 21, 2017
P=N/A, N=33, Completed, Sponsor: Wake Forest University
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2017
- | Enrollment change, Trial termination: Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients (clinicaltrials.gov) - Apr 7, 2017
P2, N=38, Terminated, Sponsor: Institut de Recherches Internationales Servier
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2017 N=450 --> 38 | Suspended --> Terminated
- | Enrollment closed, Trial primary completion date: A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: Palo Alto Veterans Institute for Research
N=450 --> 38 | Suspended --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Jul 2017
- | Trial completion, Trial primary completion date: AMIMAGE 2: Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=304, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2015
- | Trial completion: Oral Health Intervention Pilot Study for Individuals With Memory Problems (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=12, Completed, Sponsor: Duke University
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2015 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Energy Metabolism and Cognitive Aging (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=62, Completed, Sponsor: University of Cincinnati
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Dec 2016
- Phase classification, Trial primary completion date: Brain-Computer Interface System for Training Memory and Attention in Elderly (clinicaltrials.gov) - Feb 13, 2017
P2, N=240, Recruiting, Sponsor: Duke-NUS Graduate Medical School
Recruiting --> Completed | Trial primary completion date: Dec 2018 --> Dec 2016 Phase classification: P2/3 --> P2 | Trial primary completion date: Jul 2016 --> Jul 2017
- Phase classification, Enrollment change, Trial primary completion date: Energy Metabolism and Cognitive Aging (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=60, Recruiting, Sponsor: University of Cincinnati
Phase classification: P2/3 --> P2 | Trial primary completion date: Jul 2016 --> Jul 2017 Phase classification: P4 --> P=N/A | N=40 --> 60 | Trial primary completion date: Dec 2016 --> Dec 2018
- donepezil / Generic mfg.
Trial primary completion date: Donepezil and the Risk of Falls in Seniors With Cognitive Impairment (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=60, Active, not recruiting, Sponsor: Lawson Health Research Institute
Phase classification: P4 --> P=N/A | N=40 --> 60 | Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial completion, Enrollment change, Trial primary completion date: FPEB: A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (clinicaltrials.gov) - Jan 6, 2017
P1, N=48, Completed, Sponsor: Institute for Neurodegenerative Disorders
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Completed | N=155 --> 48 | Trial primary completion date: Dec 2015 --> Oct 2016